Trodelvy has become an increasingly requested medicine among Indian oncology centres treating triple-negative breast cancer, a subtype known for its aggressive course and historically limited treatment options. As demand for this antibody-drug conjugate grows, hospital procurement teams and pharmacies are asking more practical questions — less about the science, which is well established in oncology literature, and more about how to source it reliably, verify authenticity, and manage the logistics involved in supplying a complex biologic medicine. This guide addresses those sourcing questions from a distributor’s perspective.
What Is Trodelvy?
Trodelvy (Sacituzumab Govitecan) is an antibody-drug conjugate, a class of medicines that combines a targeted antibody with a cytotoxic payload, according to the manufacturer’s approved prescribing information. It is used in the treatment of certain breast cancers, including triple-negative breast cancer, as directed by an oncologist. As with all oncology biologics, the decision to prescribe Trodelvy, along with dosing and treatment monitoring, rests entirely with the treating physician, based on the current approved label and individual patient assessment. This article does not provide clinical or treatment guidance and should not be used as a substitute for consulting the prescribing information or a qualified oncologist.
Why Sourcing Antibody-Drug Conjugates Requires Extra Diligence
Antibody-drug conjugates like Trodelvy sit among the more complex categories of oncology medicines to source and distribute. Unlike small-molecule tablets, they are biologic products requiring unbroken cold chain handling, careful batch tracking, and verified authenticity at every step between manufacturer and hospital. For procurement teams, this means the sourcing process itself carries more operational weight than with conventional pharmaceuticals.
A few factors that make ADC sourcing distinct:
- Temperature sensitivity — Trodelvy, like most antibody-based therapies, requires consistent refrigerated storage (2°C to 8°C) from the point of manufacture through to administration
- Batch-specific documentation — given the complexity of biologic manufacturing, batch and lot tracking is particularly important for traceability
- Limited supplier networks — as a newer, specialised oncology medicine, Trodelvy is not available through general pharmaceutical wholesalers, requiring hospitals to work with distributors who specifically handle imported specialty oncology biologics
- Import documentation — as an imported medicine, complete import and customs documentation should accompany every shipment
What Hospitals and Pharmacies Should Verify When Sourcing Trodelvy
Before accepting delivery of Trodelvy or any comparable specialty oncology biologic, procurement teams should check the following:
- Batch number and expiry date clearly printed and matching the accompanying certificate of analysis
- Cold chain compliance documentation, including temperature logs for the shipment where available
- Manufacturer packaging authenticity — verifying consistent packaging, holography, and labelling against known authentic samples
- Complete import and supply paperwork, particularly important for institutional or bulk procurement
- Vial integrity on arrival — checking for any signs of temperature excursion, such as condensation inside packaging or compromised seals
The Growing Need for Triple-Negative Breast Cancer Medicines in India
Triple-negative breast cancer represents a meaningful proportion of breast cancer diagnoses in India, and oncology centres have historically had fewer targeted treatment options for this subtype compared to hormone receptor-positive or HER2-positive disease. As newer antibody-drug conjugates and targeted therapies become available in the Indian market, hospital pharmacies are increasingly being asked to stock and manage a wider range of specialty oncology biologics, each with its own sourcing and handling requirements. This shift places growing importance on working with distributors who understand the specific logistics these medicines demand, rather than treating them as interchangeable with conventional oncology drugs.
How Trodelvy Differs From Conventional Oncology Medicines in the Supply Chain
| Conventional Oncology Tablets | Antibody-Drug Conjugates (e.g. Trodelvy) | |
|---|---|---|
| Storage requirement | Room temperature typically | Refrigerated, 2°C–8°C |
| Cold chain during transit | Not required | Mandatory, unbroken |
| Supplier availability | Wider wholesale network | Limited specialty distributors |
| Batch complexity | Standard | Higher, biologic-specific tracking |
| Import documentation needs | Standard | More extensive |
This distinction matters directly for hospital procurement planning — a pharmacy accustomed to ordering conventional oncology tablets through general wholesale channels may need to establish a separate relationship with a specialty distributor specifically to reliably access biologics like Trodelvy.
Working With a Specialty Distributor for Oncology Biologics
Given the sourcing complexity involved, many Indian hospitals and oncology centres are consolidating their procurement of imported oncology biologics — including antibody-drug conjugates, checkpoint inhibitors, and targeted antibody therapies — through a single specialty distributor rather than managing multiple narrow supplier relationships. This approach simplifies documentation, ensures consistent cold chain standards across a hospital’s full oncology formulary, and reduces the administrative burden of tracking authenticity verification across many separate vendors.
How A.K. Pharma Supplies Trodelvy
A.K. Pharma is a licensed specialty medicine distributor in Delhi supplying genuine Trodelvy (Sacituzumab Govitecan) to hospitals, oncology centres, and pharmacies across India. As a distributor focused specifically on specialty and imported medicines, A.K. Pharma maintains certified cold chain infrastructure from procurement through last-mile hospital delivery, along with complete batch documentation for every shipment. Hospitals sourcing Trodelvy alongside other oncology biologics — including Enhertu (Trastuzumab Deruxtecan) for HER2-positive breast cancer — often find it more efficient to consolidate procurement through a single specialty oncology distributor.
Frequently Asked Questions
Is Trodelvy available in India?
Trodelvy can be sourced for hospitals and oncology centres in India through licensed specialty medicine distributors. Contact A.K. Pharma — medicine distributor in Delhi — for current availability.
What should a hospital pharmacy check when receiving a Trodelvy shipment?
Batch number, expiry date, cold chain compliance documentation, vial integrity, and complete import paperwork should all be verified against the accompanying certificate of analysis before accepting delivery.
Why is Trodelvy harder to source than standard oncology tablets?
As a temperature-sensitive antibody-drug conjugate, Trodelvy requires unbroken cold chain handling and is typically available only through distributors specialising in imported specialty oncology biologics, rather than general pharmaceutical wholesalers.
Can A.K. Pharma supply Trodelvy alongside other oncology biologics?
Yes. A.K. Pharma supplies a range of specialty oncology medicines, allowing hospitals to consolidate procurement of biologics like Trodelvy and Enhertu through a single cold chain-compliant distributor.
Who should hospitals contact to order Trodelvy?
Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current availability and pricing.
Disclaimer: This article is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.